Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Buchanan

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Journal of Clinical Orthopaedics and Trauma|February 2, 2019
The 'John Thomas' sign and pelvic fractures-Fact or humorous myth?: A systematic review and meta-analysisLouis Gerber, Abdullah E Laher, Callistus O A Enyuma, et al.
Emergency Radiology|January 17, 2018
The ultrasonographic "whirlpool sign" in testicular torsion: valuable tool or waste of valuable time? A systematic review and meta-analysisJared McDowall, Ahmed Adam, Louis Gerber, et al.
The Journal of Biological Chemistry|June 26, 2012
Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanomaVipin Yadav, Xiaoyi Zhang, Jiangang Liu, et al.
Frontiers in Behavioral Neuroscience|June 13, 2022
Precise Quantification of Behavioral Individuality From 80 Million Decisions Across 183,000 FliesBenjamin de Bivort, Sean Buchanan, Kyobi Skutt-Kakaria, et al.
Oncotarget|October 21, 2017
Preclinical characterization of abemaciclib in hormone receptor positive breast cancerRaquel Torres-Guzmán, Bruna Calsina, Ana Hermoso, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 28, 2008
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinibThomas O'Hare, Christopher A Eide, Jeffrey W Tyner, et al.
Plos One|May 31, 2014
Identification of druggable cancer driver genes amplified across TCGA datasetsYing Chen, Jeremy McGee, Xianming Chen, et al.
Cancer Discovery|January 7, 2016
Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120Shih-Hsun Chen, Youyan Zhang, Robert D Van Horn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2018
Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway SignalingMichele Dowless, Caitlin D Lowery, Terry Shackleford, et al.
Molecular Cancer Therapeutics|October 22, 2017
Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid CoadministrationGenshi Zhao, Colin F Green, Yu-Hua Hui, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Journal of Clinical Orthopaedics and Trauma|February 2, 2019
The 'John Thomas' sign and pelvic fractures-Fact or humorous myth?: A systematic review and meta-analysisLouis Gerber, Abdullah E Laher, Callistus O A Enyuma, et al.
Emergency Radiology|January 17, 2018
The ultrasonographic "whirlpool sign" in testicular torsion: valuable tool or waste of valuable time? A systematic review and meta-analysisJared McDowall, Ahmed Adam, Louis Gerber, et al.
The Journal of Biological Chemistry|June 26, 2012
Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanomaVipin Yadav, Xiaoyi Zhang, Jiangang Liu, et al.
Frontiers in Behavioral Neuroscience|June 13, 2022
Precise Quantification of Behavioral Individuality From 80 Million Decisions Across 183,000 FliesBenjamin de Bivort, Sean Buchanan, Kyobi Skutt-Kakaria, et al.
Oncotarget|October 21, 2017
Preclinical characterization of abemaciclib in hormone receptor positive breast cancerRaquel Torres-Guzmán, Bruna Calsina, Ana Hermoso, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 28, 2008
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinibThomas O'Hare, Christopher A Eide, Jeffrey W Tyner, et al.
Plos One|May 31, 2014
Identification of druggable cancer driver genes amplified across TCGA datasetsYing Chen, Jeremy McGee, Xianming Chen, et al.
Cancer Discovery|January 7, 2016
Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120Shih-Hsun Chen, Youyan Zhang, Robert D Van Horn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2018
Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway SignalingMichele Dowless, Caitlin D Lowery, Terry Shackleford, et al.
Molecular Cancer Therapeutics|October 22, 2017
Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid CoadministrationGenshi Zhao, Colin F Green, Yu-Hua Hui, et al.
Pageof 3